| Revenue growth | 19% YoY in Q4; 14% YoY in FY26. |
|---|---|
| Margins | EBITDA margin expanded 590 bps YoY to 21.7% in Q4. |
| Demand visibility | Strong growth in formulations across Europe and USA markets. |
| Management confidence | High; citing strongest quarter in history and successful platform integration. |
Growth
FY26 revenue grew 13.8% YoY to ₹34,203 Mn; EBITDA surged 59.6% YoY to ₹7,025 Mn.
Outlook
Entering FY27 with strong product pipeline, 19 R&D products, and focus on inorganic growth opportunities.
Risks
Ongoing geopolitical and maritime disruptions impacting execution; hyperinflation adjustments required for Turkey operations.
Earnings Call filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹240.77
- Market cap
- ₹10,633 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 62.1×Sector 47.3×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Promoter Selling
Promoters CA Harbor Investments and CA Hull Investments sold a combined 5.03 crore equity shares of Viyash Scientific Limited through open market transactions.
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific delivered strong Q1 FY27 results with 19.5% revenue growth and significant margin expansion. Integration is complete, and the company is now virtually debt-free, pivoting toward oncology and companion animal health.
- Call
- Guides 18% growth